Serum uric acid, influence of sacubitril/valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF von Selvaraj, S, Claggett, B.L, Veldhuisen, D.V, Anand, I.S, Pieske, B, Rouleau, J.L, Zile, M.R, Shi, V.C, Lefkowitz, M.P, McMurray, J.J.V, Solomon, S.D

Volltext

Global differences in heart failure with preserved ejection fraction: the paragon-hf trial von Tromp, J, Clagget, B.L, Jhund, P, Kober, L, Widimsky, J, Chopra, V, Ge, J, Maggioni, A.P, Martinez, F, Zannad, F, Lefkowitz, M.P, Shi, V.C, McMurray, J.J.V, Solomon, S.D, Lam, C.S.P

Volltext

Effect of sacubitril/valsartan on cognitive function in patients with HFpEF: a prespecified analysis of PARAGON-HF von Dewan, P, Jhund, P.S, Anand, I.S, Desai, A.S, Gong, J, Lefkowitz, M.P, Pieske, B, Rizkala, A.R, Shah, S.J, Van Veldhuisen, D.J, Zannad, F, Zile, M.R, Solomon, S.D, McMurray, J.J.V

Volltext

Upregulation of phagocytosis and candidicidal activity of macrophages exposed to the immunostimulant, acemannan von Stuart, R.W., Lefkowitz, D.L., Lincoln, J.A., Howard, K., Gelderman, M.P., Lefkowitz, S.S.

Volltext